Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

roche pharma ag (3001678) - zalcitabin - filmtablette - teil 1 - filmtablette; zalcitabin (26597) 0,375 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

roche pharma ag (3001678) - zalcitabin - filmtablette - teil 1 - filmtablette; zalcitabin (26597) 0,75 milligramm

Europäische Union - Deutsch - EMA (European Medicines Agency)

roche registration limited - emicizumab - hämophilie a - antihämorrhagika - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra kann verwendet werden in allen altersgruppen.

Europäische Union - Deutsch - EMA (European Medicines Agency)

roche registration gmbh - baloxavir marboxil - influenza, mensch - antivirale mittel zur systemischen anwendung - treatment of influenzaxofluza is indicated for the treatment of uncomplicated influenza in patients aged 1 year and above. post exposure prophylaxis of influenzaxofluza is indicated for post-exposure prophylaxis of influenza in individuals aged 1 year and above. xofluza should be used in accordance with official recommendations.

Europäische Union - Deutsch - EMA (European Medicines Agency)

roche registration gmbh - satralizumab - neuromyelitis optica - immunsuppressiva - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Europäische Union - Deutsch - EMA (European Medicines Agency)

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - ophthalmika - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

f. hoffmann-la roche ag - filgrastimum adnr - durchstechflaschen - filgrastimum adnr 30 mio. u., natrii acetas trihydricus, polysorbatum 80, sorbitolum, wasser ad iniectabilia q.s. zu einer lösung anstelle von 1 ml. - neutropenie - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

f. hoffmann-la roche ag - filgrastimum adnr - fertigspritzen - filgrastimum adnr 30 mio. u., natrii acetas trihydricus, polysorbatum 80, sorbitolum, wasser ad iniectabilia q.s. zu einer lösung anstelle von 0,5 ml. - neutropenie - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

f. hoffmann-la roche ag - filgrastimum adnr - fertigspritzen - filgrastimum adnr 48 mio. u., natrii acetas trihydricus, polysorbatum 80, sorbitolum, wasser ad iniectabilia q.s. zu einer lösung anstelle von 0,5 ml. - neutropenie - biotechnologika

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

orochemie gmbh & co. kg (3270220) - ethanol 96% ((95.1% - 96.9% (v/v), 92.6% - 95.2% (g/g))); 1-propanol (ph.eur.) - lösung zur anwendung auf der haut - teil 1 - lösung zur anwendung auf der haut; ethanol 96% ((95.1% - 96.9% (v/v), 92.6% - 95.2% (g/g))) (00006) 57,6 gramm; 1-propanol (ph.eur.) (03244) 10 gramm